Social Media Ideas for Inclisiran

Latest updates for Inclisiran

Fresh curated links around inclisiran are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Post angles to try

Share the most useful takeaway for your audience.

Turn one article into a quick practical checklist.

Ask your audience how this shift affects their work.

Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

biopharmadive.com /1 month ago

AstraZeneca, Ionis drug fails big heart disease study in major setback

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio...

Read source

biopharmadive.com /1 month ago

Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.

Read source

drugs.com /1 month ago

FDA Clears First Cholesterol Pill, Lipfendra, To Rival Costly Injections

THURSDAY, July 16, 2026 — A new daily pill will give people with stubbornly high cholesterol a cheaper, needle-free way to drive their levels down. The U.S. Food and Drug Administr...

Read source

fiercebiotech.com /2 weeks ago

Silence brings the noise to Takeda with phase 2 blood cancer win

A phase 2 trial of Silence Therapeutics’ divesiran has hit its primary endpoint, emboldening the biotech to gear up for late-phase development of a potential challenger to Takeda a...

Read source

fiercebiotech.com /1 month ago

Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds

In vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.

Read source

refractor.io /1 month ago

Once-daily LDL cholesterol-smashing pill gets FDA approval

The US Food and Drug Administration (FDA) has just approved a game-changing cholesterol drug, the first of its kind in a class that's otherwise administered by injection.

Read source

biopharmadive.com /2 weeks ago

‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit

Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead mov...

Read source

biopharmadive.com /3 weeks ago

Alnylam plunges as earnings deliver ‘one-two punch’

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

Read source

biopharmadive.com /4 days ago

Regeneron to challenge Ipsen as FDA clears bone disease drug

Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Sources covering Inclisiran

newatlas.com

Recent coverage from public sources

Public source

biopharmadive.com

Recent coverage from public sources

Public source

drugs.com

Recent coverage from public sources

Public source

fiercebiotech.com

Recent coverage from public sources

Public source

Recent searches

Artificial Intelligence Machine Learning Data Science Data Engineering Business Intelligence Web Development Software Development Software Testing Programming JavaScript DevOps Cyber Security Product Management Project Management Design UX UX Research Graphic Design Video Production Video Editing